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Abstract
Aims: An association between inflammatory bowel dis-
ease (IBD) and spondyloarthropathies (SpA) has re-
peatedly been reported. The aim of the present study
was to investigate whether serologic markers of IBD, e.g.
antibodies against Saccharomyces cerevisiae (ASCA),
antibodies against exocrine pancreas (PAB) and perinu-
clear antineutrophil cytoplasmic antibodies (pANCA)
are present in HLA-B27-associated SpA. Methods: 87
patients with HLA-B27-positive SpA and 145 controls
were tested for ASCA, PAB and pANCA employing
ELISA or indirect immunofluorescence, respectively.
Antibody-positive patients were interviewed regarding
IBD-related symptoms using a standardized question-
naire. Results/Conclusion: When compared to the con-
trols, ASCA IgA but not ASCA IgG levels were signifi-
cantly increased in patients with SpA, in particular in
ankylosing spondylitis (AS) and undifferentiated SpA
(uSpA). pANCA were found in increased frequency in
patients with SpA whereas PAB were not detected. The
existence of autoantibodies was not associated with
gastrointestinal symptoms but sustains the presence of
a pathophysiological link between bowel inflammation
and SpA.
Copyright © 2004 S. Karger AG, Basel
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are
associated with peripheral and axial arthropathies [1–4].
The findings of several studies have suggested that a sub-
stantial number of patients with spondyloarthropathies
(SpA) may have asymptomatic intestinal inflammation,
usually affecting the ileum [5–14]. A further development
of CD or UC was observed in about 7% of these patients
[8]. The pattern of joint and spine involvement in patients
with inflammatory bowel disease (IBD) and in classic SpA
such as ankylosing spondylitis can be similar. Thus, it has
been hypothesized that the intestinal inflammation might
be of pathogenic relevance for the development of arthri-
tis and that the ileal inflammation in SpA could represent
a pre- or subclinical form of CD.
In IBD, various autoantibodies have been described
and are considered as serological markers for CD or UC.
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Table 1. Characteristics of the study population
Spondyloarthropathies
AS ReA PsA uSpA all patients
with SpA
Control
individuals
Patients 51 8 9 19 87 145
Male/female ratio 37/14 4/4 8/1 13/6 62/25 71/74
Age, years (mean B SD) 39.4B1.1 44.8B13 36B14.4 34.4B1.2 38.5B11.8 44.6B12.5
Age, years (range) 24–70 21–63 18–65 19–54 18–70 18–68
Anti-Saccharomyces cerevisiae antibodies (ASCA) appear
in approximately two thirds of CD patients [15–17],
whereas antibodies against exocrine pancreas (PAB) are
present in about one third of the patients [18, 19]. These
antibodies are highly specific for IBD. Perinuclear anti-
neutrophil cytoplasmatic antibodies (pANCA) are found
in 45–80% of patients with UC [20, 21]. Familial cluster-
ing of these antibodies has been described, with an
increased prevalence among first-degree relatives of pa-
tients with IBD [22–26]. Considering that first-degree rel-
atives of IBD patients display a 10- to 15-fold increased
risk of developing either CD or UC throughout their life-
time, these observations are compatible with a role of the
respective antibody as a preclinical marker of IBD.
An increased prevalence of antibodies with a close cor-
relation to IBD in patients with SpA could represent an
additional pathophysiological link between both disease
entities. Therefore, in the present study we investigated if
IBD-associated autoantibodies, e.g. ASCA, pANCA and
PAB, are present in HLA-B27-associated SpA and if the
presence of these antibodies correlates with clinical symp-
toms suggestive for IBD.
Patients and Methods
Study Population
The study population comprised 145 healthy unrelated blood
donors and 87 patients with HLA-B27-positive SpA (51 patients with
ankylosing spondylitis (AS), 8 with reactive arthritis (ReA), 9 with
psoriatic arthritis (PsA) and 19 with undifferentiated SpA (uSpA)).
Cases with a previous diagnosis of CD or UC were excluded. All
patients had previously been tested for HLA-B27. The baseline char-
acteristics of the study population are depicted in table 1. Sera were
obtained by centrifugation of venous whole blood samples and stored
at –20°C until use.
Patients who were tested positive for autoantibodies were inter-
viewed regarding IBD-related symptoms and manifestations using a
standardized questionnaire. The following parameters were assessed:
stool frequency (^3 or 13 per day), anal discharge of mucus or
blood,
abdominal pain, weight loss and dermal or ocular lesions. Addition-
ally, information about a positive family history of IBD, previous
endoscopic or radiological findings and consumption of non-steroi-
dal anti-inflammatory drugs (NSAIDs) were obtained.
Enzyme-Linked Immunosorbent Assays (ELISA) for ASCA
Sera of patients and controls were tested for both ASCA IgA and
IgG using Medizym® ASCA IgA and Medizym® ASCA IgG ELISA
kits (Medipan Diagnostica, Selchow, Germany). Briefly, 100 Ìl of
serum and control samples diluted 1/51 in the ready-for-use diluent
were added to 96-well microtiter plates coated with the specific anti-
gen (mannan from S. cerevisiae). After 60 min incubation at 37°C
the unbound serum components were removed, the plates were
washed and then 100 Ìl of anti-human IgA or IgG antibodies conju-
gated with horseradish peroxidase were added to each well. The
plates were washed again and 100 Ìl of substrate containing hydro-
gen peroxide were added. After 10 min the enzyme reaction was
stopped by adding 100 Ìl of stop solution and the plates were read at
450 vs. 620 nm using a microplate reader. Diluted human sera pro-
vided by the manufacturer served as internal controls. For qualita-
tive evaluation, the binding index (BI = ODsample/ODcut-off control) was
calculated. The cut-off control for the IgA assay was the 20 U/ml
calibrator, whereas for the IgG assay the cut-off control was pro-
vided. The sample was considered positive at a BI of 61.0. For every
sample, two independent analyses on the same plate were carried out
and the mean of the two analyses was used in further evaluations.
Indirect Immunofluorescence (IIF)
Antineutrophil cytoplasmic antibodies (ANCA) and PAB were
visualized by standard IIF as described in detail elsewhere [19].
Briefly, sera were diluted 1:10 in phosphate-buffered saline with
0.2% Tween and tested for ANCA on commercially available glass
slides containing three Biochips for each sample with ethanol-fixed
neutrophils, formalin-fixed neutrophils and monkey liver cryostat
sections (Euroimmun AG, Lübeck, Germany), allowing differentia-
tion of ANCA patterns from antinuclear antibodies patterns. For the
detection of PAB, Biochips with monkey pancreas cryostat sections
mounted on glass slides (Euroimmun AG) were employed. Fluores-
cein-conjugated goat antihuman IgG was used as secondary anti-
body, according to the manufacturer’s instructions. The immunoflu-
orescence patterns were assessed under a fluorescence microscope by
two independent investigators. The pANCA titer was determined
using progressive dilutions of the positive sera up to 1:1,000.
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Fig. 1. ASCA IgA levels in controls and patients with HLA-B27-posi-
tive SpA. * Correspond to 56 and 270 U/ml, respectively.
Fig. 2. ASCA IgG levels in controls and patients with HLA-B27 SpA:
BI = binding index = ODsample/ODcut-off control.
ELISA for ANCA Antigen Specificity
All IIF pANCA-positive sera were investigated for six common
antigen specificities: proteinase 3, myeloperoxidase, elastase, cathep-
sin G, lactoferrin and bactericidal/permeability increasing protein
(BPI) using a commercially available ELISA kit (ANCA-Profil (IgG),
Euroimmun AG), according to the manufacturer’s instructions.
Statistics
The ASCA concentrations in the different groups were compared
employing the Mann-Whitney U test. Categorical variables were
compared using Fisher’s exact test. p values !0.05 were considered
significant. The statistical analysis was performed using SPSS soft-
ware.
Results
ASCA IgA and ASCA IgG
ASCA IgA levels were significantly higher in patients
with HLA-B27-associated SpA than in healthy controls
(p ! 0.0001) (fig. 1). When the group of patients with SpA
was divided into clinical subgroups, significantly higher
ASCA IgA levels were observed in patients with AS and
uSpA (p ! 0.0001) whereas in patients with ReA and PsA,
levels were only slightly increased compared to healthy
controls (p ! 0.05). At the qualitative evaluation, using
the cut-off of 20 U/ml, 5 patients with AS tested positive
whereas all patients with ReA, PsA or uSpA and controls
were negative (p ! 0.01).
The ASCA IgG concentrations were not significantly
different in patients with SpA when compared to the con-
trols (fig. 2). Using the cut-off supplied by the manufac-
turer, 2 patients with AS (1 of them also positive for
ASCA IgA) and 1 control were positive for ASCA IgG.
The combined frequency for ASCA IgA and ASCA IgG
was significantly increased in patients with AS when com-
pared to the controls (p ! 0.001).
pANCA
Four patients with HLA-B27-positive SpA (2 with AS
and 2 with uSpA) but none of the controls were ANCA-
positive in IIF (p ! 0.05). All ANCA-positive sera gave a
perinuclear fluorescence pattern (pANCA). The pANCA
titer was 1:10 in 2 cases, 1:100 in 1 case and 1:320 in 1
case. When tested in ELISA for the six common antigen
specificities (proteinase 3, myeloperoxidase, elastase, ca-
thepsin G, lactoferrin and BPI), none of the four IIF
pANCA-positive sera was positive.
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PAB
PAB were not detected in any of the controls or the
patients with SpA.
Clinical Data
When interviewed using the standard questionnaire,
symptoms or signs suggestive of IBD were not reported by
any of the antibody-positive patients. A familial history of
IBD was also not reported. Ileocolonoscopy had been per-
formed in only 2 of the patients, in both cases 3 years
before collection of the sera and no changes suggestive
for IBD had been observed. Six of the 11 antibody-posi-
tive patients received NSAIDs at the time of blood sam-
pling, 4 of them were positive for ASCA and 2 positive for
pANCA.
Discussion
Herein we report an increased frequency of IBD-spe-
cific autoantibodies in patients with HLA-B27-associated
SpA. Compared to healthy controls, the levels of ASCA
IgA were significantly increased in patients with SpA, in
particular in the group of patients with AS and uSpA. At
the qualitative evaluation using the cut-off control 20 U/
ml, as suggested by the manufacturer for the diagnosis of
CD, 5 patients with AS tested positive but none of the
controls or patients with other SpA (p ! 0.01). However,
the cut-off 20 U/ml for the Medizym® ASCA IgA kit
might be too high for detecting AS, yielding a sensitivity
of 13.7% at a specificity of 100%. A lower cut-off for this
kit was also suggested for the diagnosis of CD [17]. More-
over, a recent study detecting ASCA IgA in AS and uSpA
suggested a cut-off of 11 U/ml [28]. Using this cut-off, the
sensitivity for the diagnosis of AS or uSpA in our study
yielded 83% by a specificity of 87%. A cut-off of 15 U/ml
gave a sensitivity of 70% for AS or uSpA at a specificity of
94%. The levels of ASCA IgG were not raised in SpA.
Two patients with AS and 1 control tested positive at the
qualitative evaluation.
An increased frequency of pANCA in patients with
SpA was also observed. Two patients with AS and 2
patients with uSpA but none of the controls tested posi-
tive for pANCA. However, this frequency is low com-
pared to the reported frequencies for pANCA in UC
(140%) [20, 21]. When employed in ELISA, six common
antigen specificities (proteinase 3, myeloperoxidase, elas-
tase, cathepsin G, lactoferrin and BPI) were not bound by
the four pANCA-positive sera. In two sera the titer might
have been too low for a positive result in the ELISA
(1:10). However, as two sera exhibited fairly high titers,
these findings could be compatible with a distinct antigen
specificity which was not assessed by the ELISA. In con-
trast to ASCA and PAB, ANCA are not exclusively found
in UC but are also seromarkers for other disease entities
such as vasculitic disorders or primary sclerosing cholan-
gitis. The immunofluorescence pattern and the respective
ANCA target antigens in UC generally differ from those
observed in vasculitis disorders. Data in the literature
regarding the presence of ANCA in HLA-B27-associated
disorders are scarce and contradictory. However, occur-
rence of ANCA was sporadically observed in patients
with AS [29, 30], ReA [31], or anterior uveitis [32]. Data
regarding intestinal involvement or IBD-related symp-
toms in antibody-positive patients are lacking in these
studies.
Based on the available literature data it appears possi-
ble that the presence of IBD-specific autoantibodies re-
presents yet undiagnosed cases of CD or UC in patients
with SpA. Although antibody-positive patients denied
any suggestive symptoms, pre- or subclinical IBD is not
excluded. Because endoscopy was not performed prospec-
tively we cannot rule out that such cases might have been
missed. Noteworthy, apart from the 5 AS patients with
titers 120 U/ml, the serum levels for ASCA IgA were sig-
nificantly higher in SpA compared to the controls. Litera-
ture data about the prevalence of concomitant ileocolitis
in SpA are inconsistent due to different diagnostic meth-
ods such as scintigraphy by 99mTc leukocytes [33] or retro-
spective endoscopic findings [5–14]. Interestingly, the lat-
ter reported histologic abnormalities in up to 28% of
healthy controls [34]. Furthermore, a recent study failed
to demonstrate an association between the ASCA IgA lev-
els and histologically confirmed bowel inflammation or
the number of lymphoid follicles in gut biopsy specimens
from patients with AS and uSpA [28]. Some cases of ileitis
or colitis in SpA might have been caused by the adminis-
tration of NSAIDs. The latter impair the integrity of the
intestinal mucosa which could facilitate contact of lumi-
nal (bacterial or yeast) antigens with antigen-presenting
cells. This mechanism was also proposed for expression of
disease-specific autoantibodies in IBD [35]. However,
increased intestinal permeability in CD patients does not
associate with the ASCA status [35]. In addition, in
patients with AS, subclinical gut inflammation and in-
creased intestinal permeability have also been reported
independent from the use of NSAIDs [36]. In the present
study, 6 of the 11 ASCA- or pANCA-positive patients
received NSAID therapy.
IBD-Specific Autoantibodies in HLA-B27-
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The increased frequency of IBD-specific antibodies
lends some further credibility to the notion that the ileitis
in HLA-B27-associated SpA and in CD might be patho-
physiologically related. A similar immunologic back-
ground in SpA and IBD is supported by various observa-
tions [for overview, see 37], such as an upregulation of the
adhesion molecule E-cadherin [38], an increase in the
number of lymphoid follicles [39], a predominant Th1
cytokine profile [40] or the presence of macrophages
expressing the scavenger receptor CD163 [41] in intesti-
nal mucosa, which were demonstrated not only in CD but
also in HLA-B27-associated rheumatologic diseases. Re-
cently, an identical T-cell expansion in the colonic muco-
sa and the synovium of a patient with reactive spondy-
loarthropathy was also described [42].
Future trials might focus on the following topics:
patients with SpA should be offered a prospective ileoco-
lonoscopy and the prevalence of mucosal inflammatory
changes should be compared between ASCA- or pANCA-
positive and -negative patients. Moreover, mucosal per-
meability should be assessed in order to provide a possible
explanation for the presence of these antibodies in pa-
tients with normal endoscopic findings. Data should be
compared after stratification of patients with respect to
the use of NSAIDs. Finally, long-term observation of the
patients could reveal if the presence of serum autoanti-
bodies such as ASCA or pANCA is a predictive marker
for subsequent development of an IBD or is rather an
independent phenomenon in SpA.
Acknowledgement
The authors gratefully acknowledge the technical support of
M. Siwy.
References
1 De Vlam K, Mielants H, Cuvelier C, De Keyser
F, Veys EM, De Vos M: Spondyloarthropathy
is underestimated in inflammatory bowel dis-
ease: Prevalence and HLA association. J Rheu-
matol 2000;27:2860–2865.
2 Salvarani C, Vlachonikolis IG, van der Heijde
DM, Fornaciari G, Macchioni P, Beltrami M,
Olivieri I, Di Gennaro F, Politi P, Stockbrugger
RW, Russel MG: European Collaborative IBD
Study Group: Musculoskeletal manifestations
in a population-based cohort of inflammatory
bowel disease patients. Scand J Gastroenterol
2001;36:1307–1313.
3 Palm O, Moum B, Ongre A, Gran JT: Preva-
lence of ankylosing spondylitis and other spon-
dyloarthropathies among patients with inflam-
matory bowel disease: A population study (the
IBSEN study). J Rheumatol 2002;29:511–515.
4 Steer S, Jones H, Hibbert J, Kondeatis E,
Vaughan R, Sanderson J, Gibson T: Low back
pain, sacroiliitis, and the relationship with
HLA-B27 in Crohn’s disease. J Rheumatol
2003;30:518–522.
5 Leirisalo-Repo M, Turunen U, Stenman S,
Helenius P, Seppala K: High frequency of
silent inflammatory bowel disease in spondyl-
arthropathy. Arthritis Rheum 1994;37:23–31.
6 Mielants H, Veys EM, Cuvelier C, de Vos M:
Ileocolonoscopic findings in seronegative spon-
dyloarthropathies. Br J Rheumatol 1988;27:
95–105.
7 Mielants H, Veys EM, De Vos M, Cuvelier C,
Goemaere S, De Clercq L, Schatteman L, Ele-
waut D: The evolution of spondyloarthropa-
thies in relation to gut histology I. Clinical
aspects. J Rheumatol 1995;22:2266–2272.
8 De Vos M, Mielants H, Cuvelier C, Elewaut A,
Veys E: Long-term evolution of gut inflamma-
tion in patients with spondyloarthropathy.
Gastroenterology 1996;110:1696–1703.
9 Mielants H, Veys EM, Cuvelier C, De Vos M,
Goemaere S, De Clercq L, Schatteman L, Gy-
selbrecht L, Elewaut D: The evolution of spon-
dyloarthropathies in relation to gut histology.
III. Relation between gut and joint. J Rheuma-
tol 1995;22:2279–2284.
10 De Vos M, Cuvelier C, Mielants H, Veys E,
Barbier F, Elewaut A: Ileocolonoscopy in se-
ronegative spondylarthropathy. Gastroenterol-
ogy 1989;96:339–344.
11 Porzio V, Biasi G, Corrado A, De Santi M, Vin-
digni C, Viti S, Bayeli PF, Marcolongo R: Intes-
tinal histological and ultrastructural inflamma-
tory changes in spondyloarthropathy and rheu-
matoid arthritis. Scand J Rheumatol 1997;26:
92–98.
12 Simenon G, Van Gossum A, Adler M, Rickaert
F, Appelboom T: Macroscopic and microscop-
ic gut lesions in seronegative spondyloarthrop-
athies. J Rheumatol 1990;17:1491–1494.
13 Lee YH, Ji JD, Kim JS, Bak YT, Lee CH, Kim
CH, Chae YS, Song GG: Ileocolonoscopic and
histologic studies of Korean patients with an-
kylosing spondylitis. Scand J Rheumatol 1997;
26:473–476.
14 Grillet B, de Clerck L, Dequeker J, Rutgeerts P,
Geboes K: Systematic ileocolonoscopy and
bowel biopsy study in spondylarthropathy. Br J
Rheumatol 1987;26:338–340.
15 Main J, McKenzie H, Yeaman GR, Kerr MA,
Robson D, Pennington CR, Parratt D: Anti-
body to Saccharomyces cerevisiae (bakers’
yeast) in Crohn’s disease. BMJ 1988;297:
1105–1106.
16 Quinton JF, Sendid B, Reumaux D, Duthilleul
P, Cortot A, Grandbastien B, Charrier G, Tar-
gan SR, Colombel JF, Poulain D: Anti-Saccha-
romyces cerevisiae mannan antibodies com-
bined with antineutrophil cytoplasmic autoan-
tibodies in inflammatory bowel disease: Preva-
lence and diagnostic role. Gut 1998;42:788–
791.
17 Ruemmele FM, Targan SR, Levy G, Dubinsky
M, Braun J, Seidman EG: Diagnostic accuracy
of serological assays in pediatric inflammatory
bowel disease. Gastroenterology 1998;115:
822–829.
18 Stocker W, Otte M, Ulrich S, Normann D,
Finkbeiner H, Stocker K, Jantschek G, Scriba
PC: Autoimmunity to pancreatic juice in
Crohn’s disease. Results of an autoantibody
screening in patients with chronic inflammato-
ry bowel disease. Scand J Gastroenterol 1987;
139:41–52.
19 Folwaczny C, Noehl N, Endres SP, Loeschke
K, Fricke H: Antineutrophil and pancreatic
autoantibodies in first-degree relatives of pa-
tients with inflammatory bowel disease. Scand
J Gastroenterol 1998;33:523–528.
20 Duerr RH, Targan SR, Landers CJ, Sutherland
LR, Shanahan F: Anti-neutrophil cytoplasmic
antibodies in ulcerative colitis. Comparison
with other colitides/diarrheal illnesses. Gastro-
enterology 1991;100:1590–1596.
21 Cambridge G, Rampton DS, Stevens TR,
McCarthy DA, Kamm M, Leaker B: Anti-neu-
trophil antibodies in inflammatory bowel dis-
ease: Prevalence and diagnostic role. Gut 1992;
33:668–674.
54 Digestion 2004;70:49–54 Török/Glas/Gruber/Brumberger/Strasser/
Kellner/Märker-Hermann/Folwaczny
22 Lee JC, Lennard-Jones JE, Cambridge G: Anti-
neutrophil antibodies in familial inflammatory
bowel disease. Gastroenterology 1995;108:
428–433.
23 Annese V, Andreoli A, Andriulli A, Dinca R,
Gionchetti P, Latiano A, Lombardi G, Piepoli
A, Poulain D, Sendid B, Colombel JF: Familial
expression of anti-Saccharomyces cerevisiae
mannan antibodies in Crohn’s disease and ul-
cerative colitis: A GISC study. Am J Gastroen-
terol 2001;96:2407–2412.
24 Glas J, Torok HP, Vilsmaier F, Herbinger KH,
Hoelscher M, Folwaczny C: Anti-Saccharo-
myces cerevisiae antibodies in patients with
inflammatory bowel disease and their first-
degree relatives: Potential clinical value. Diges-
tion 2002;66:173–177.
25 Folwaczny C, Noehl N, Tschop K, Endres SP,
Heldwein W, Loeschke K, Fricke H: Goblet
cell autoantibodies in patients with inflamma-
tory bowel disease and their first-degree rela-
tives. Gastroenterology. 1997;113:101–106.
26 Folwaczny C, Noehl N, Endres SP, Heldwein
W, Loeschke K, Fricke H: Antinuclear autoan-
tibodies in patients with inflammatory bowel
disease. High prevalence in first-degree rela-
tives. Dig Dis Sci 1997;42:1593–1597.
27 Vermeire S, Joossens S, Peeters M, Monsuur F,
Marien G, Bossuyt X, Groenen P, Vlietinck R,
Rutgeerts P. Comparative study of ASCA (anti-
Saccharomyces cerevisiae antibody) assays in
inflammatory bowel disease. Gastroenterology
2001;120:827–833.
28 Hoffman IE, Demetter P, Peeters M, De Vos
M, Mielants H, Veys EM, De Keyser F: Anti-
Saccharomyces cerevisiae IgA antibodies are
raised in ankylosing spondylitis and undiffer-
entiated spondyloarthropathy. Ann Rheum
Dis 2003;62:455–459.
29 Koh WH, Dunphy J, Dixey J, Calin A,
McHugh NJ, Maddison PJ: Atypical antineu-
trophil cytoplasmic antibodies in patients with
ankylosing spondylitis. Br J Rheumatol 1995;
34:695–696.
30 Weinerth JD, Stoffel MP, Csernok E, Gross
WL: Are antineutrophil cytoplasmic antibodies
associated with spondyloarthropathies? Br J
Rheumatol 1996;35:1032–1033.
31 Locht H, Peen E, Skogh T: Antineutrophil
cytoplasmic antibodies in reactive arthritis. J
Rheumatol 1995;22:2304–2306.
32 Gordon LK, Eggena M, Holland GN, Weisz
JM, Braun J: pANCA antibodies in patients
with anterior uveitis: Identification of a marker
antibody usually associated with ulcerative co-
litis. J Clin Immunol 1998;18:264–271.
33 Lionetti P, Pupi A, Veltroni M, Fonda C, Ca-
vicchi MC, Azzari C, Falcini F: Evidence of
subclinical intestinal inflammation by 99m-
technetium leukocyte scintigraphy in patients
with HLA-B27-positive juvenile onset active
spondyloarthropathy. J Rheumatol 2000;27:
1538–1541.
34 Smale S, Natt RS, Orchard TR, Russell AS,
Bjarnason I: Inflammatory bowel disease and
spondylarthropathy. Arthritis Rheum 2001;44:
2728–2736.
35 Vermeire S, Peeters M, Vlietinck R, Joossens S,
Den Hond E, Bulteel V, Bossuyt X, Geypens B,
Rutgeerts P: Anti-Saccharomyces cerevisiae an-
tibodies (ASCA), phenotypes of IBD, and intes-
tinal permeability: a study in IBD families.
Inflamm Bowel Dis 2001;7:8–15.
36 Mielants H, De Vos M, Goemaere S, Schel-
straete K, Cuvelier C, Goethals K, Maertens
M, Ackerman C, Veys EM: Intestinal mucosal
permeability in inflammatory rheumatic dis-
eases. II. Role of disease. J Rheumatol 1991;18:
394–400.
37 Baeten D, De Keyser F, Mielants H, Veys EM:
Immune linkages between inflammatory bowel
disease and spondyloarthropathies. Curr Opin
Rheumatol 2002;14:342–347.
38 Demetter P, Baeten D, De Keyser F, De Vos
M, Van Damme N, Verbruggen G, Vermeulen
S, Mareel M, Elewaut D, Mielants H, Veys EM,
Cuvelier CA: Subclinical gut inflammation in
spondyloarthropathy patients is associated
with upregulation of the E-cadherin/catenin
complex. Ann Rheum Dis 2000;59:211–216.
39 Demetter P, Van Huysse JA, De Keyser F, Van
Damme N, Verbruggen G, Mielants H, De Vos
M, Veys EM, Cuvelier CA: Increase in lym-
phoid follicles and leukocyte adhesion mole-
cules emphasizes a role for the gut in spondy-
loarthropathy pathogenesis. J Pathol 2002;198:
517–522.
40 Van Damme N, De Vos M, Baeten D, Demet-
ter P, Mielants H, Verbruggen G, Cuvelier C,
Veys EM, De Keyser F: Flow cytometric analy-
sis of gut mucosal lymphocytes supports an
impaired Th1 cytokine profile in spondyloar-
thropathy. Ann Rheum Dis 2001;60:495–499.
41 Demetter P, De Vos M, De Keyser F, Van de
Velde S, Baeten D, Van Damme N, Verbrug-
gen G, Mielants H, Veys EM, Cuvelier CA:
Increased number of macrophages in non-
inflamed colon of patients with spondyloar-
thropathy, a human model of early Crohn’s dis-
ease. Gastroenterology 2000; 118:A342.
42 May E, Marker-Hermann E, Wittig BM, Zeitz
M, Meyer zum Buschenfelde KH, Duchmann
R: Identical T-cell expansions in the colon mu-
cosa and the synovium of a patient with ente-
rogenic spondyloarthropathy. Gastroenterol-
ogy 2000;119:1745–1755.
